相似文献
1
Factors Influencing the Risk of No-Reflow Development.
Anatol J Cardiol. 2024 Mar 6;28(5):255-6. doi: 10.14744/AnatolJCardiol.2024.4224.
2
[Influencing factor analysis of no-reflow phenomenon after reperfusion in patients with chronic limb ischemia associated with acute thrombosis].
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2012 Mar;26(3):336-40.
3
Predictive value of N-terminal pro-B-type natriuretic peptide (NT-pro BNP) combined with D-dimer for no-reflow phenomenon in patients with acute coronary syndrome after emergency of percutaneous coronary intervention.
Bioengineered. 2021 Dec;12(1):8614-8621. doi: 10.1080/21655979.2021.1988361.
4
No-Reflow Prediction in Acute Coronary Syndrome During Percutaneous Coronary Intervention: The NORPACS Risk Score.
Circ Cardiovasc Interv. 2024 Apr;17(4):e013738. doi: 10.1161/CIRCINTERVENTIONS.123.013738. Epub 2024 Mar 15.
5
Simple clinical risk score for no-reflow prediction in patients undergoing primary Percutaneous Coronary Intervention with acute STEMI.
Pak J Med Sci. 2015;31(3):576-81. doi: 10.12669/pjms.313.7484.
6
Predictive factors for development of the no-reflow phenomenon in patients with reperfused anterior wall acute myocardial infarction.
J Am Coll Cardiol. 2001 Aug;38(2):472-7. doi: 10.1016/s0735-1097(01)01405-x.
7
Prediction of no-reflow phenomenon in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Medicine (Baltimore). 2020 Jun 26;99(26):e20152. doi: 10.1097/MD.0000000000020152.
8
Risk Factors for No-Reflow Phenomenon after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome.
Rev Invest Clin. 2017 May-Jun;69(3):139-145. doi: 10.24875/ric.17002190.
9
Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction.
Am J Cardiol. 2013 Jan 15;111(2):178-84. doi: 10.1016/j.amjcard.2012.09.015. Epub 2012 Oct 27.
10
No-Reflow Phenomenon in Central Retinal Artery Occlusion: Incidence, Risk Factors, and Clinical Implications.
PLoS One. 2015 Nov 23;10(11):e0142852. doi: 10.1371/journal.pone.0142852. eCollection 2015.
引用本文的文献
1
Reply to Letter to the Editor: 'Factors Influencing the Risk of No-Reflow Development'.
Anatol J Cardiol. 2024 Mar 1;28(5):257-61. doi: 10.14744/AnatolJCardiol.2024.4226.
本文引用的文献
1
The Association Between Atherogenic Index of Plasma and No-Reflow Phenomenon in Acute Coronary Syndrome.
Anatol J Cardiol. 2023 Dec 1;27(12):712-719. doi: 10.14744/AnatolJCardiol.2023.3381. Epub 2023 Oct 9.
2
Association of CHADS-VASc score with thrombus burden in patients with acute myocardial infarction undergoing SVG-PCI.
Herz. 2022 Oct;47(5):456-464. doi: 10.1007/s00059-021-05070-x. Epub 2021 Oct 4.
3
The "no reflow" phenomenon following acute myocardial infarction: mechanisms and treatment options.
J Cardiol. 2014 Aug;64(2):77-85. doi: 10.1016/j.jjcc.2014.03.008. Epub 2014 May 3.
4
Coronary No-reflow Phenomenon.
Curr Treat Options Cardiovasc Med. 2005 May;7(1):75-80. doi: 10.1007/s11936-005-0008-0.
Zotero 插件